The Clínic Foundation presents 21 innovative projects at BIO-Europe Spring

BIO-Europe Spring is taking place in Barcelona from 11th to 13th March. It is the springtime counterpart to BIO-Europe, Europe's largest partnering conference serving the global biotechnology industry. The event, held in Barcelona for the second time,continues the tradition of providing life science companies with high caliber partnering opportunities. The Innovation Management Office of the Clínic Foundation for Biomedical Research, a professional team that manages its own projects as well as innovation from Hospital Clínic of Barcelona, IDIBAPS and CRESIB, is there with a highly competitive portfolio of innovative ideas to be licensed.

The portfolio consists of up to 21 state-of-the-art innovative projects of diverse typologies: therapeutics, medical devices, diagnosis & prognosis and software solutions. It ranges from new approaches to the treatmentof stroke, intimal hyperplasia, Crohn’s disease, hepatitis or pulmonary hypertension to a new vaccine against malaria, a device to enhance pelvic floor training and tests and biomarkers for diabetes, rheumatoid arthritis, mantle cell lymphoma, chronic lymphocytic leukemia, prostate cancer, chronic nephropathy or heart failure. Among others it also includes a user-friendly application to manage R&D Innovation – CLINCUBATOR®. All together, the Clínic Foundation offers very interesting projects in a very interesting event that turns Barcelona, again, into the focus of European biomedical research.

The Clínic Foundation is a non-profit institution with the mission to promote, support and manage the biomedical research and innovation in Hospital Clínic of Barcelona and its research associated institutes (IDIBAPS and CRESIB). Globally, this foundation manages the research of around 750 principal investigators. By participating in BIO-Europe Spring they will establish contacts with biotech companies, pharmaceutical companies, institutional financial firms, private investors or industry related service companies. Some of the major pharmaceutical and biotech companies, such as Roche, GSK Vaccines, Genentech, Alexion Pharmaceuticals, Genzyme, TCD Pharma, Shire Pharma or Biokit, have already showed their interest in discussing the Portfolio of Licensing and Partnering Opportunities presented by the Clínic Foundation.

For further information: Biocat